Sign Out
Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see Pharmacology: Pharmacodynamics under Actions).
22 mcg: Rebif is indicated for the treatment of relapsing multiple sclerosis.
In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see Pharmacology: Pharmacodynamics under Actions).
44 mcg: Rebif is indicated for the treatment of patients with single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing relapsing multiple sclerosis (see Pharmacology: Pharmacodynamics under Actions); patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google